in-vitro and in-vivo antileishmanial activity of a compound derived of platinum, oxaliplatin, against leishmania major

This study aimed to evaluate the antileishmanial efficacy of oxaliplatin against leishmaniamajor (l. major) both in-vitro and in-vivo. the ic_50, cc_50, and si of oxaliplatin againstpromastigotes, murine macrophages, raw 264.7 cells, and intramacrophage amastigotes ofl. major were investigated in-vitro. the effects of this drug on intracellular amastigotes werealso assayed, and the percentage of infectivity and iir were calculated. flow cytometry wasperformed to assay apoptosis, using 50 and 100 μg/ml of oxaliplatin in the promastigotesand macrophages. in-vivo, the balb/c mice were classified into three groups, receivingoxaliplatin, glucantime, and phosphate-buffered saline for one month, respectively. the lesionsize, ifn-γ, and il-4 levels, and parasite burden were also evaluated in the animals. after 72h, the ic_50 and cc_50 of oxaliplatin against promastigotes and macrophages were respectively0.5 and 66.78 μg/ml. the apoptosis of promastigotes and macrophages using 50 μg/mlof oxaliplatin was 7.25% and 2.14%, respectively, while apoptosis induced at 100 μg/mlwas 15.48% and 2.80%, respectively. similar to the glucantime group, the mice treated withoxaliplatin showed a lower parasite burden and smaller lesions, compared with the pbs group(p < 0.01). furthermore, higher ifn-γ levels were reported in mice receiving oxaliplatin incomparison with those receiving pbs (p < 0.01). the current findings indicated the efficacyof oxaliplatin against promastigote and amastigote forms of leishmania and l. major-inducedleishmaniasis.